Agio

(redirected from agios)
Also found in: Dictionary, Thesaurus, Legal, Financial.

Agio

 

a deviation toward a higher market price of gold than the quantity of paper money that nominally represents the given gold quantity.

Agio is usually computed as a percentage. Agio also means a deviation toward a higher market rate for paper money, promissory notes, and other securities than their face value. The deviation toward a lower rate is called disagio.

References in periodicals archive ?
Latest news and deals relating to the Agios Pharmaceuticals, Inc.
PBR Staff Writer Published 25 March 2015 Agios Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational medicine AG-348 to treat pyruvate kinase (PK) deficiency, a rare form of hemolytic anemia.
We are pleased to be collaborating with Penn and value the contributions of their scientists to this exciting field, said, Agios chief executive officer David Schenkein.
In connection with the financing, Perry Karsen, Celgene's chief operations officer, has been named board member of Agios.
6 October 2011 - US biopharmaceutical firms Celgene Corp (NASDAQ:CELG) and Agios Pharmaceuticals Inc have agreed on a one-year extension of their strategic alliance, focused on cancer metabolism, Reuters reported on Wednesday.
In the article, Agios scientists reported the first inhibitors of mutant IDH1 that show good potency in a glioblastoma cell line harboring IDH1 mutation and achieve robust tumor 2-HG inhibition in the tumor xenograft model.
This publication arises from collaborative work conducted between Agios scientists and colleagues at the California Institute of Technology and the Genomics Institute of the Novartis Research Foundation.
Biopharmaceutical company Agios Pharmaceuticals Inc (Nasdq:AGIO) today announced that it has priced its initial public offering of 5,888,888 shares of its common stock at a public offering price of USD18.
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in cancer metabolism, announced today the publication of a new study that provides further evidence of the link between a mutated metabolic enzyme and acute myeloid leukemia (AML), one of the most common types of leukemia in adults.
To support and drive these efforts, Agios has built a robust platform integrating cancer biology, metabolomics, biochemistry and informatics to enable target and biomarker identification.
The strength of our science and success of our efforts to date are a direct result of the amazing people at Agios," said Duncan Higgons, chief operating officer of Agios.
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, announced today that preclinical data from Agios research were highlighted in two poster sessions and an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2012 being held March 31-April 4, 2012 in Chicago.